Genentech

X @genentech

⚔ Compare ☆ Follow Own this channel?

🔄 Data last refreshed 14 hours ago

🤝

Make a deal with Genentech

🔒 Paid proposals held safely in escrow — released only when the work's approved.

Followers

123.2K

Posts

7.8K

Following

225

Account age

17 yrs

🎁 Free analysisfor Genentech

🕵️Fake Followers CheckReal-audience % & bot risk→ 📊Engagement rateBenchmarked vs. peers→ 💰What they chargeFair sponsored-post price→

Known for

#Breaking: New positive Phase III results demonstrate superiority of an investigational molecule over standard-of-care KRAS G12C inhibitors in the first global head-to-head study in KRAS G12C-mutant non-small cell lung cancer: https://t.co/Bsxy2BeZ51

6.3K views #Breaking: New positive Phase III results demonstrate superiority of an investigational molecule over standard-of-care KRAS G12C inhibitors in the first global head-to-head study in KRAS G12C-mutant non-small cell lung cancer: https://t.co/Bsxy2BeZ51

#Breaking: The @US_FDA granted priority review to our treatment for primary membranous nephropathy (pMN), a chronic, idiopathic kidney condition.
If approved, it would be the first FDA-approved therapy specifically indicated to treat this disease. Read more:

2.6K views #Breaking: The @US_FDA granted priority review to our treatment for primary membranous nephropathy (pMN), a chronic, idiopathic kidney condition. If approved, it would be the first FDA-approved therapy specifically indicated to treat this disease. Read more:

#Breaking: Today meaningful data from our Phase III study in systemic lupus erythematosus was published in @NEJM. Learn more: https://t.co/SOuSuH4695

2.5K views #Breaking: Today meaningful data from our Phase III study in systemic lupus erythematosus was published in @NEJM. Learn more: https://t.co/SOuSuH4695

#Breaking: The @US_FDA has granted priority review for our treatment for thyroid eye disease (TED), an autoimmune disease that can lead to facial disfigurement and vision threatening complications if left untreated. Learn more: https://t.co/N2R9G2wVAn

2.4K views #Breaking: The @US_FDA has granted priority review for our treatment for thyroid eye disease (TED), an autoimmune disease that can lead to facial disfigurement and vision threatening complications if left untreated. Learn more: https://t.co/N2R9G2wVAn

📊 Post performance

2.1K

Avg views / post

1.7%

Reach vs followers

Sep 2008

On X since

🔥 Top post: #Breaking: New positive Phase III results demonstrate superiorit · 6.3K views

📊 Activity & format

Posting cadence

0.75 / week

A lower-frequency account — each post lands with more weight.

Content mix

Mostly video

Recent: 12 video · 3 image · 3 text.

Follower / following

547×

Follows 225 back. A strong ratio — an audience that follows them, not a follow-for-follow network.

Recent posts

View on X ↗

▶ 🔥 Top post #Breaking: New positive Phase III results demonstrate superiority of an investigational molecule over standard-of-care KRAS G12C inhibitors in the first global head-to-head study in KRAS G12C-mutant non-small cell lung cancer: https://t.co/Bsxy2BeZ51 6.3K❤ 10🔁 5

Today we announced an expansion of our Hillsboro, OR site with a new device fill-finish facility. This investment reflects our continued commitment to Hillsboro and the region's workforce as we build end-to-end U.S. drug manufacturing capa… 2.3K❤ 3🔁 3 Today marks a major milestone: the topping out of our first-ever East Coast manufacturing facility in Holly Springs, NC. The final beam placement reflects our progress and deep commitment to the region’s workforce, community, and long-term… 2.8K❤ 3

▶ #Breaking: The @US_FDA granted priority review to our treatment for primary membranous nephropathy (pMN), a chronic, idiopathic kidney condition. If approved, it would be the first FDA-approved therapy specifically indicated to treat this … 2.6K❤ 9🔁 3

▶ #Breaking: We are presenting data across our Alzheimer’s disease portfolio at #AAIC2026, highlighting our dedication to detect, slow and hopefully one day prevent this devastating disease. Learn more: https://t.co/RFBiMvh6FD 2.2K❤ 4🔁 1

#Breaking: The @US_FDA has granted priority review for our treatment for thyroid eye disease (TED), an autoimmune disease that can lead to facial disfigurement and vision threatening complications if left untreated. Learn more: https://t.c… 2.4K❤ 7🔁 2

▶ #Breaking: @US_FDA accepted the supplemental Biologics License Application (sBLA) supporting a combination treatment for people living with relapsed or refractory large B-cell lymphoma, including diffuse large B-cell lymphoma: https://t.co… 1.6K❤ 3🔁 2

▶ #Breaking: @US_FDA accepted our supplemental Biologics License Application (sBLA) and granted Priority Review for an investigational adjuvant combination regimen in a certain type of stage III colon cancer: https://t.co/CHs4atW9cE 2.3K❤ 6🔁 4

▶ #Breaking: @US_FDA accepted the New Drug Application, under Priority Review, for our investigational oral selective estrogen receptor degrader (SERD) as a treatment for adults with ER+, HER2-, early-stage breast cancer. Learn more: https:/… 1.9K❤ 5

▶ #Breaking: We are presenting data at the upcoming #ADASciSessions from our obesity portfolio, highlighting our differentiated approaches to addressing unmet needs for people living with #obesity. Learn more: https://t.co/b0DWFD2hlz 1.6K❤ 4

▶ #Breaking: We’re presenting new data across breast, lung, gastrointestinal, bladder and blood cancers at the American Society of Clinical Oncology (#ASCO26). Learn more about our efforts to transform cancer care: https://t.co/b5QhB8Z8mR 2.1K❤ 2🔁 2

▶ #Breaking: @US_FDA approved our immunotherapy as an adjuvant treatment option for adults with muscle-invasive bladder cancer (#MIBC) after surgery (cystectomy) who have circulating tumor DNA (ctDNA) molecular residual disease. Learn more: … 2.1K❤ 6🔁 1

💡 Facts

🗓️Joined X in 2008 — 17 years ago.

👁️Averages 2.1K views per post.

📤Posts about 0.8× per week.

💬0.01% engagement rate.

🏅Earned the 100K Followers for passing 100K followers.

🕵️ Fake follower check

Estimated

37/100

Low Credibility score

66%

Mixed Real audience

Medium Fake-follower risk

High Data confidence

Est. 66% real, active audience · Medium fake-follower risk.
Low engagement (~1.7% of followers engage each post) — a sign of an inflated or inactive audience.
Organic base — far more followers than accounts it follows.
Established account (17+ years old).
0.01% engagement — below the ~14.4% typical for this size.

Heuristic estimate from engagement, follower ratios, account age & growth — a screening signal, not a guarantee.

About

Official Twitter for Genentech. See our community guidelines here: http://ow.ly/1sSw30lmszz

📸 Gallery

$#Breaking: @US_FDA accepted the supplemental Biologics License Application (sBLA) supporting a combination treatment for people living with relapsed or refractory large B-cell lymphoma, including diffuse large B-cell lymphoma: https://t.co/XVqebWzC5R$

🔀 Audience overlap

Estimated

Estimated shared audience with similar creators — useful for avoiding overlap (or doubling down) when planning a campaign.

DEA HQ 14%

EL PAÍS América 14%

ESTER DEAN 14%

Sarbananda Sonowal 13%

The Washington Times 11%

IRENA 10%

More like this

Frequently asked questions

How much does Genentech charge for a sponsorship?

Genentech hasn't published fixed prices yet. Send a proposal through SocialDB and agree terms directly — your payment is held in escrow until the work is approved.

How do I contact Genentech for a brand deal or collaboration?

Send a paid deal or collab request right here on SocialDB — we notify Genentech, and once they accept, your payment is held safely in escrow and released when the work is approved. You don't need to track down an email.

How many followers does Genentech have?

Genentech has 123,178 followers on X.

Auto-generated from X's public data — no affiliation with or endorsement by SocialDB. Is this you? Claim it · Remove